DESTINY-Breast11与DESTINY-Breast05两项研究入选主席研讨会（Presidential Symposium），凸显德曲妥珠单抗在治疗HER2阳性早期乳腺癌中的潜在价值
TROPION-Breast02研究数据将展示德达博妥单抗在转移性三阴性乳腺癌这一最具侵袭性的乳腺癌分型中的治疗潜力
POTOMAC研究的无病生存期数据与MATTERHORN研究的生存期数据将展示度伐利尤单抗在早期膀胱癌与胃癌治疗中的获益
上海
2025年10月14日 /美通社/ — 阿斯利康将于2025年10月17日至21日召开的欧洲肿瘤内科学会（ESMO）年会上，凭借⾏业领先的多样化产品与管线布局的全新研究数据，进一步彰显其重新定义癌症治疗格局的雄心壮志。
本次大会上，阿斯利康将公布逾95项摘要，涵盖9款已获得批准药物及9款潜在新药，包括2项入选重要主席研讨会（Presidential Symposium）的摘要以及26项口头报告。
其中主要亮点包括：
DESTINY-Breast11：评估德曲妥珠单抗序贯THP方案（紫杉醇、曲妥珠单抗及帕妥珠单抗）用于高风险HER2阳性早期乳腺癌新辅助治疗的III期临床研究（主席研讨会1，摘要#291O）。
DESTINY-Breast05：评估德曲妥珠单抗用于HER2阳性早期乳腺癌（新辅助治疗后存在残留浸润病灶并具有高复发风险）的III期临床研究（主席研讨会1，摘要#LBA1）。
TROPION-Breast02：评估德达博妥单抗用于一线治疗无法接受免疫治疗的局部复发性不可手术或转移性三阴性乳腺癌（TNBC）患者的III期临床研究（优选论文摘要#LBA21）。
POTOMAC
：评估度伐利尤单抗联合卡介苗（BCG）诱导与维持治疗，用于高危非肌层浸润性膀胱癌（NMIBC）患者的III期临床研究（优选论文摘要#LBA108）。
MATTERHORN：公布III期临床研究的最终总生存期（OS）结果，评估度伐利尤单抗联合FLOT化疗作为可切除的早期和局部晚期的胃和胃⻝管结合部腺癌（GEJ）患者围手术期治疗中的临床获益（优选论文摘要#LBA81）。
阿斯利康全球执行副总裁、全球肿瘤研发负责人高书璨（Susan Galbraith）表示：”我们正加速推进多元创新疗法管线，以变革乳腺癌患者的治疗格局。在本届ESMO大会上，我们将公布TROPION-Breast02、DESTINY-Breast11和DESTINY-Breast05研究的数据和重要进展。同时，我们也将展示新一代潜在抗肿瘤新药的数据，包括saruparib联合新型激素疗法用于前列腺癌领域，靶向叶酸受体的抗体偶联药物torvu-sam用于卵巢癌领域，以及rilvegostomig用于在非小细胞肺癌领域。”
阿斯利康全球执行副总裁，肿瘤业务负责人Dave Fredrickson表示：”我们业界领先的肿瘤产品组合在本次ESMO持续展现强劲势头，首次公布了四项关键研究的数据。其中，不仅有德曲妥珠单抗和德达博妥单抗在乳腺癌领域的重大进展，度伐利尤单抗的POTOMAC试验结果也证明了免疫疗法为早期膀胱癌治疗带来的益处，进而阐释我们的策略——将前沿治疗引入癌症早期这一患者最能够获益的阶段。”
其他亮点包括：
FONTANA：评估靶向叶酸受体α（FRα）的抗体药物偶联物AZD5335用于铂耐药复发性卵巢癌患者的I/IIa期首次人体临床试验（简短口头报告摘要#1065MO）。
PETRANHA：评估saruparib联合雄激素受体通路抑制剂用于治疗转移性前列腺癌患者的I/II期临床研究（简短口头报告摘要#2384MO）。
ARTEMIDE
-01：评估rilvegostomig用于检查点抑制剂初治的转移性非小细胞肺癌（NSCLC）患者的I/II期临床研究（简短口头报告摘要#1853MO）。
FLAURA2：在奥希替尼合化疗治疗晚期EGFR突变NSCLC患者的FLAURA2 III期临床研究中存在不良预后因素患者的探索性OS分析（优选论文摘要#LBA77）。
CAPItello
-281：卡匹色替联合阿比特龙和雄激素剥夺疗法（ADT）用于PTEN缺陷的新发转移性激素敏感性前列腺癌（mHSPC）的III期临床研究（优选论文摘要#2383O）。
TROPION
-PanTumor03：评估德达博妥单抗联合rilvegostomig治疗局晚期或转移性尿路上皮癌（a/mUC）患者的疗效： II期TROPION-PanTumor03研究结果结果（简短口头报告摘要 #3072MO）
BEGONIA
：德达博妥单抗联合度伐利尤单抗用于既往未经治疗的不可切除、局部晚期或转移性三阴性乳腺癌（TNBC）患者的BEGONIA Ib/II期试验最终结果（口头报告摘要#555MO）。
阿斯利康与第⼀三共联合开发和商业化德曲妥珠单抗与德达博妥单抗；与默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）联合开发和商业化奥拉帕利；与和黄医药合作开发和商业化赛沃替尼。Rilvegostomig是一种靶向PD-1和TIGIT的双特异性抗体，其中TIGIT部分源自Compugen公司临床阶段的抗TIGIT抗体COM902。
阿斯利康在2025年ESMO年会期间的重要演讲[1]
主要作者
摘要标题
报告详情(CEST)
抗体偶联药物
Harbeck, N
DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan
alone (T-DXd) or followed by paclitaxel + trastuzumab +
pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+
early breast cancer (eBC)
Abstract #291O
Presidential 1
18 October 2025
4:30 PM
Geyer, C
Trastuzumab deruxtecan (T-DXd) vs trastuzumab
emtansine (T-DM1) in patients (pts) with high-risk human
epidermal growth factor receptor 2–positive (HER2+)
primary breast cancer (BC) with residual invasive disease
after neoadjuvant therapy (tx): Interim analysis of
DESTINY-Breast05
Abstract #LBA1
Presidential 1
18 October 2025
4:52 PM
Dent, R.
First-line (1L) datopotamab deruxtecan (Dato-DXd) vs
chemotherapy in patients with locally recurrent inoperable
or metastatic triple-negative breast cancer (mTNBC) for
whom immunotherapy was not an option: Primary results
from the randomised, phase 3 TROPION-Breast02 trial
Abstract #LBA21
Proffered Paper Session
19 October 2025
9:25 AM
Loibl, S
Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane
+ trastuzumab + pertuzumab (THP) for patients with
HER2+ advanced/metastatic breast cancer: additional
analysis of DESTINY-Breast09 in key subgroups of interest
Abstract #LBA18
Proffered Paper Session
19 October 2025
8:30 AM
Rha, SY
Datopotamab deruxtecan (Dato-DXd) + rilvegostomig
(rilve) in patients (pts) with locally advanced or metastatic
urothelial cancer (a/mUC): Results from the phase 2
TROPION-PanTumor03 study
Abstract #3072MO
Mini Oral Session
17 October 2025
4:10 PM
Oaknin, A
First-in-human study of AZD5335, a folate receptor α
(FRα)-targeted antibody-drug conjugate, in patients with
platinum-resistant recurrent ovarian cancer
Abstract #1065MO
Mini Oral Session
19 October 2025
10:53 AM
Schmid, P
Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as
first-line (1L) treatment (tx) for unresectable locally
advanced/metastatic triple-negative breast cancer
(a/mTNBC): Final results from the phase 1b/2 BEGONIA
study
Abstract #555MO
Mini Oral Session
20 October 2025
10:50 AM
Raghav, K
Trastuzumab deruxtecan (T DXd) in patients (pts) with
HER2-positive (HER2+) metastatic colorectal cancer
(mCRC): Final analysis of DESTINY-CRC02, a
randomized, phase 2 trial
Abstract #737P
Poster Session
Peng, Z
Trastuzumab deruxtecan (T-DXd) in patients (pts) with
HER2+ gastric cancer (GC) or gastroesophageal junction
adenocarcinoma (GEJA) who received prior anti-HER2
treatment (Tx) other than / in addition to trastuzumab in
DESTINY-Gastric06 (DG-06)
Abstract #2105P
Poster Session
Shen, L
Risk of hepatitis B virus reactivation (HBVr) in patients
(pts) with past or resolved HBV or inactive chronic HBV
infection treated with trastuzumab deruxtecan (T-DXd) in
the DESTINY-Gastric06 (DG-06) trial
Abstract #2175P
Poster Session
Pietrantonio, F
Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM)
plus paclitaxel (PTX) in second-line (2L) treatment of
patients (pts) with HER2+ unresectable/metastatic gastric
cancer (GC)/gastroesophageal junction adenocarcinoma
(GEJA): Additional data from DESTINY-Gastric04 (DG-04)
Abstract #2099P
Poster Session
Makker, V
Trastuzumab deruxtecan (T-DXd) for pretreated patients
(pts) with HER2-expressing solid tumors: DESTINY-
PanTumor02 (DP-02) Part 1 final analysis
Abstract #957P
Poster Session
Lee, J-Y
Trastuzumab deruxtecan (T-DXd) in pretreated patients
(pts) with HER2-expressing solid tumors: exploratory
biomarker analysis of DESTINY-PanTumor02 (DP-02) Part
1
Abstract #145P
Poster Session
免疫肿瘤学
Tabernero, J
MATTERHORN Phase III trial of Imfinzi (durvalumab)
perioperative Imfinzi (durvalumab) plus FLOT
chemotherapy in patients with resectable, early-stage and
locally advanced gastric and gastroesophageal junction
(GEJ) cancers
Abstract #LBA81
Proffered Paper Session
17 October 2025
2:00 PM
De Santis, M
Durvalumab (D) in Combination with Bacillus Calmette-
Guérin (BCG) for BCG-naïve, High-risk Non-muscle-
invasive Bladder Cancer (NMIBC): Results from the Phase
3, Open-label, Randomised POTOMAC Trial
Abstract #LBA108
Proffered Paper Session
17 October 2025
2:10 PM
Larkin, J
First results from RAMPART: An international phase 3
randomised-controlled trial of adjuvant durvalumab
monotherapy or combined with tremelimumab for resected
primary renal cell carcinoma (RCC) led by MRC CTU at
UCL
Abstract #LBA93
Proffered Paper Session
18 October 2025
9:20 AM
Aghajanian, C
Durvalumab + paclitaxel/carboplatin + bevacizumab
followed by durvalumab, bevacizumab + olaparib
maintenance in patients with newly diagnosed non-tBRCA-
mutated advanced ovarian cancer: final overall survival
from DUO-O/ENGOT-ov46/GOG-3025
Abstract #LBA44
Mini Oral Session
19 October 2025
11:31 AM
Goss, G
CCTG BR.31: Adjuvant durvalumab (D) in resected non-
small-cell lung cancer (NSCLC): final overall survival (OS)
and minimal residual disease (MRD) analyses
Abstract #LBA68
Mini Oral Session
20 October 2025
3:20 PM
Heymach, J
Association of radiomic features ± on-treatment ctDNA
detection with treatment outcomes in patients with
resectable NSCLC: exploratory analyses from AEGEAN
Abstract #LBA70
Mini Oral Session
20 October 2025
3:50 PM
Wermke, M
Tarlatamab with first-line chemoimmunotherapy for
extensive stage small cell lung cancer (ES-SCLC):
DeLLphi-303 study
Abstract #2757O
Proffered Paper Session
18 October 2025
8:30 AM
Loibl, S
Durvalumab in Combination with Neoadjuvant
Chemotherapy in Early Triple-Negative Breast Cancer
(TNBC) – Long-term Analysis from the GeparNuevo Trial
Abstract #292MO
Mini Oral Session
19 October 2025
10:15 AM
Van der Heijden, M
Health-related quality of life (HRQoL) from the NIAGARA
trial of perioperative durvalumab (D) plus neoadjuvant
chemotherapy (NAC) in muscle-invasive bladder cancer
(MIBC)
Abstract #3069MO
Mini Oral Session
17 October 2025
4:00 PM
Sangro, B
Pooled efficacy and safety outcomes with tremelimumab
plus durvalumab in participants (pts) with unresectable
hepatocellular carcinoma (uHCC) from the combined
China extension and global cohorts in the Phase 3
HIMALAYA study
Abstract #1494P
Poster Session
Westin, S
Durvalumab plus carboplatin/paclitaxel followed by
durvalumab for endometrial cancer: Tumour mutational
burden-high subpopulation efficacy analyses from the
DUO-E trial
Abstract #1117P
Poster Session
Leal, TA
Global quantitative assessment of multidisciplinary team
(MDT) care in early-stage NSCLC
Abstract #1794P
Poster Session
Reck, M
Neoadjuvant durvalumab (D) + chemotherapy (CT)
followed by either surgery (Sx) and adjuvant D or CRT and
consolidation D in patients (pts) with resectable or
borderline resectable stage IIB–IIIB NSCLC: interim
analysis (IA) of the phase 2 MDT-BRIDGE study
Abstract #LBA65
Proffered Paper Session
18 October 2025
9:15 AM
Maruki, Y
CELEBRATE Study (JCOG2107E): A Multicenter, Open-
label, Phase III Trial of Etoposide, Carboplatin, and
Durvalumab in First-line Treatment of Unresectable or
Recurrent Digestive NEC
Abstract #1734TiP
Poster Session
Oudard, S
A phase IIIb, open-label, single-arm, global study of
perioperative durvalumab (D) with neoadjuvant dose-
dense methotrexate, vinblastine, doxorubicin, and cisplatin
(ddMVAC) or gemcitabine/cisplatin (gem/cis) in patients
with muscle-invasive bladder cancer (MIBC) (NIAGARA-2)
Abstract #3133eTiP
ePoster Session
双特异性抗体
Chul Cho, B
Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT
Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve
Metastatic Non-Small-Cell Lung Cancer (mNSCLC):
ARTEMIDE-01
Abstract #1853MO
Mini Oral Session
20 October 2025
10:25 AM
Slomovitz, BM
A randomized Phase 3 study of first-line (1L) trastuzumab
deruxtecan (T-DXd) with rilvegostomig or pembrolizumab
in patients with HER2-expressing, mismatch repair-
proficient (pMMR), primary advanced or recurrent
endometrial cancer (EC): DESTINY-Endometrial01/GOG-
3098/ENGOT-EN24
Abstract #1223TiP
Poster Session
Naidoo, J
ARTEMIDE-Lung04: A Phase 3, randomised, double-blind,
global study of rilvegostomig or pembrolizumab
monotherapy as first-line (1L) treatment for patients with
metastatic non-small cell lung cancer (mNSCLC) and
programmed cell death ligand-1 (PD-L1) expression ≥50%
Abstract #2025TiP
Poster Session
肿瘤驱动因子和耐药性
Jänne, PA
FLAURA2: exploratory overall survival (OS) analysis in
patients (pts) with poor prognostic factors treated with
osimertinib (osi) ± platinum-pemetrexed chemotherapy
(CTx) as first-line (1L) treatment for EGFR-mutated
(EGFRm) advanced NSCLC
Abstract #LBA77
Proffered Paper Session
17 October 2025
4:56 PM
Mayer, E
Patient-reported outcomes (PROs) from the SERENA-6
trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i)
for emergent ESR1m during first-line (1L) endocrine-based
therapy and ahead of disease progression in patients (pts)
with HR+/HER2- advanced breast cancer (ABC)
Abstract #486MO
Mini Oral Session
20 October 2025
10:25 AM
Arriola, E
Molecular residual disease (MRD) analysis from the
LAURA study of osimertinib (osi) in unresectable (UR)
stage III EGFR-mutated (EGFRm) NSCLC
Abstract #1817MO
Mini Oral Session
20 October 2025
2:55 PM
Park, YH
Visual symptom questionnaire results from SERENA-6, a
Phase 3 study of switch to camizestrant (CAMI) + CDK4/6
inhibitor (CDK4/6i) at emergence of ESR1m during first-
line (1L) therapy for patients (pts) with HR+/HER2-
advanced breast cancer (ABC)
Abstract #528P
Poster Session
Chu, Q
SAVANNAH: Safety and tolerability of osimertinib (osi) +
savolitinib (savo) in EGFRm advanced NSCLC with MET
overexpression and/or amplification (OverExp/Amp)
following disease progression on osi
Abstract #1955P
Poster Session
Rotow, J
MET testing and treatment (tx) sequencing after
progression on first line (1L) osimertinib (osi) in patients
(pts) with EGFRm advanced NSCLC and acquired MET
overexpression and/or amplification (OverExp/Amp):
Interim analysis of a global real world (rw) study
Abstract #1967P
Poster Session
Yu, Y
ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo)
plus osimertinib (osi) versus chemotherapy (chemo) in
MET-amplified (METamp) advanced NSCLC after disease
progression (PD) on EGFR tyrosine kinase inhibitor (TKI)
Abstract #1954P
Poster Session
DNA损伤应答
Azad, AA
First interim efficacy analysis of the Phase 1/2 PETRANHA
trial of saruparib + androgen receptor pathway inhibitors
(ARPI) in patients (pts) with metastatic prostate cancer
(mPC)
Abstract #2384MO
Mini Oral Session
17 October 2025
2:35 PM
Fizazi, K
A Phase 3 study of capivasertib (capi) + abiraterone (abi)
vs placebo (pbo) + abi in patients (pts) with PTEN deficient
de novo metastatic hormone-sensitive prostate cancer
(mHSPC): CAPItello-281
Abstract #2383O
Proffered Paper Session
19 October 2025
11:19 AM
Rugo, HS
Capivasertib with fulvestrant as first- and second-line
endocrine therapy in PIK3CA/AKT1/PTEN-altered
hormone receptor-positive advanced breast cancer:
Subgroup analysis from the Phase 3 CAPItello-291 trial
Abstract #526P
Poster Session
Gao, Q
Final overall survival (OS) analysis of L-MOCA: olaparib
maintenance monotherapy in patients (pts) with platinum-
sensitive relapsed ovarian cancer (PSR OC)
Abstract #1090P
Poster Session
AI
驱动的临床试验
Gonuguntla, HK
Real-World Validation of AI-defined Lung Nodule
Malignancy Score (qXR-LNMS) in Predicting Risk of Lung
Cancer: Interim results from Phase 2
Abstract #2978P
Poster Session
[1]阿斯利康在2025年ESMO年会将公布逾90个摘要，涵盖其产品和管线中的分子药物
关于阿斯利康肿瘤领域的研究
阿斯利康正引领着肿瘤领域的⼀场革命，致力提供多元化的肿瘤治疗方案，以科学探索肿瘤领域的复杂性，发现、研发并向患者提供改变生命的药物。
阿斯利康专注于最具挑战性的肿瘤疾病，通过持续不断的创新，阿斯利康已经建立了行业领先的多元化的 产品组合和管线，持续推动医疗实践变⾰，改变患者体验。
阿斯利康以期重新定义癌症治疗并在未来攻克癌症。
关于阿斯利康
阿斯利康（LSE/STO/Nasdaq: AZN）是⼀家科学至上的全球生物制药企业，专注于研发、生产及营销处方类药品，重点关注肿瘤、罕见病以及包括心血管肾脏及代谢、呼吸及免疫在内的生物制药等领域。阿斯利康全球总部位于英国剑桥，业务遍布超过125个国家，创新药物惠及全球数百万患者。更多信息，请访问www.astrazeneca.com。
关于阿斯利康中国
阿斯利康自1993年进入中国以来，专注中国患者需求最迫切的治疗领域，包括肿瘤、心血管、肾脏、代谢、呼吸、消化、罕见病、疫苗抗体及自体免疫等，已将40多款创新药物带到中国。阿斯利康中国总部位于上海，并在上海和北京设立全球战略研发中心，在北京、广州、杭州、成都、青岛设立区域总部，在无锡、泰州、青岛建立全球生产供应基地，向全球70多个市场输送优质创新药品。
声明：本文研究中涉及的多种药品用法尚未在中国获批适应症，阿斯利康不推荐任何未被批准的药品使用。
SOURCE 阿斯利康